Literature DB >> 19549916

Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease.

Dolores Di Vizio1, Jayoung Kim, Martin H Hager, Matteo Morello, Wei Yang, Christopher J Lafargue, Lawrence D True, Mark A Rubin, Rosalyn M Adam, Rameen Beroukhim, Francesca Demichelis, Michael R Freeman.   

Abstract

Oncosomes have recently been described as membrane-derived microvesicles secreted by cancer cells, which transfer oncogenic signals and protein complexes across cell boundaries. Here, we show the rapid formation and secretion of oncosomes from DU145 and LNCaP human prostate cancer cells. Oncosome formation was stimulated by epidermal growth factor receptor activation and also by overexpression of membrane-targeted Akt1. Microvesicles shed from prostate cancer cells contained numerous signal transduction proteins and were capable of activating rapid phospho-tyrosine and Akt pathway signaling, and stimulating proliferation and migration, in recipient tumor cells. They also induced a stromal reaction in recipient normal cells. Knockdown of the actin nucleating protein Diaphanous Related Formin 3 (DRF3/Dia2) by RNA interference enhanced rates of oncosome formation, indicating that these structures resemble, and may be identical to, nonapoptotic membrane blebs, a feature of the amoeboid form of cell motility. Analysis of primary and metastatic human prostate tumors using 100K single nucleotide polymorphism arrays revealed a significantly higher frequency of deletion of the locus encoding DRF3 (DIAPH3) in metastatic tumors (P = 0.001) in comparison with organ-confined tumors. Fluorescence in situ hybridization confirmed increased chromosomal loss of DIAPH3 in metastatic tumors in a different cohort of patients (P = 0.006). These data suggest that microvesicles shed from prostate cancer cells can alter the tumor microenvironment in a manner that may promote disease progression. They also show that DRF3 is a physiologically relevant protein that seems to regulate this process.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19549916      PMCID: PMC2853876          DOI: 10.1158/0008-5472.CAN-08-3860

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer.

Authors:  S A Tahir; G Yang; S Ebara; T L Timme; T Satoh; L Li; A Goltsov; M Ittmann; J D Morrisett; T C Thompson
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

2.  Disruption of the Diaphanous-related formin Drf1 gene encoding mDia1 reveals a role for Drf3 as an effector for Cdc42.

Authors:  Jun Peng; Bradley J Wallar; Akiko Flanders; Pamela J Swiatek; Arthur S Alberts
Journal:  Curr Biol       Date:  2003-04-01       Impact factor: 10.834

3.  Alix (ALG-2-interacting protein X), a protein involved in apoptosis, binds to endophilins and induces cytoplasmic vacuolization.

Authors:  Christine Chatellard-Causse; Beatrice Blot; Nadine Cristina; Sakina Torch; Marc Missotten; Remy Sadoul
Journal:  J Biol Chem       Date:  2002-05-28       Impact factor: 5.157

4.  Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer.

Authors:  J T Dong; J C Boyd; H F Frierson
Journal:  Prostate       Date:  2001-11-01       Impact factor: 4.104

5.  Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis.

Authors:  Erik Sahai; Christopher J Marshall
Journal:  Nat Cell Biol       Date:  2003-08       Impact factor: 28.824

6.  Exosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins.

Authors:  Flip H Jansen; Jeroen Krijgsveld; Angelique van Rijswijk; Gert-Jan van den Bemd; Mirella S van den Berg; Wytske M van Weerden; Rob Willemsen; Lennard J Dekker; Theo M Luider; Guido Jenster
Journal:  Mol Cell Proteomics       Date:  2009-02-09       Impact factor: 5.911

7.  Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function.

Authors:  Rosalyn M Adam; Jayoung Kim; Jianqing Lin; Anna Orsola; Liyan Zhuang; Dana C Rice; Michael R Freeman
Journal:  Endocrinology       Date:  2002-12       Impact factor: 4.736

8.  Differential gene expression in breast cancer cell lines and stroma-tumor differences in microdissected breast cancer biopsies revealed by display array analysis.

Authors:  Albert S Mellick; Chris J Day; Stephen R Weinstein; Lyn R Griffiths; Nigel A Morrison
Journal:  Int J Cancer       Date:  2002-07-10       Impact factor: 7.396

9.  Phosphoprotein analysis using antibodies broadly reactive against phosphorylated motifs.

Authors:  Hui Zhang; Xiangming Zha; Yi Tan; Peter V Hornbeck; Allison J Mastrangelo; Dario R Alessi; Roberto D Polakiewicz; Michael J Comb
Journal:  J Biol Chem       Date:  2002-07-31       Impact factor: 5.157

10.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection.

Authors:  C Li; W H Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more
  166 in total

1.  Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer.

Authors:  Wei Yang; Quan Cai; Vivian W Y Lui; Patrick A Everley; Jayoung Kim; Neil Bhola; Kelly M Quesnelle; Bruce R Zetter; Hanno Steen; Michael R Freeman; Jennifer R Grandis
Journal:  J Proteome Res       Date:  2010-06-04       Impact factor: 4.466

2.  Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes.

Authors:  Joanna Kowal; Guillaume Arras; Marina Colombo; Mabel Jouve; Jakob Paul Morath; Bjarke Primdal-Bengtson; Florent Dingli; Damarys Loew; Mercedes Tkach; Clotilde Théry
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

3.  Circulating Extracellular Vesicles in Normotension Restrain Vasodilation in Resistance Arteries.

Authors:  Miranda E Good; Luca Musante; Sabrina La Salvia; Nancy L Howell; Robert M Carey; Thu H Le; Brant E Isakson; Uta Erdbrügger
Journal:  Hypertension       Date:  2019-11-25       Impact factor: 10.190

4.  Coordinated Regulation of Intracellular Fascin Distribution Governs Tumor Microvesicle Release and Invasive Cell Capacity.

Authors:  James W Clancy; Christopher J Tricarico; Daniel R Marous; Crislyn D'Souza-Schorey
Journal:  Mol Cell Biol       Date:  2019-01-16       Impact factor: 4.272

Review 5.  Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large oncosomes.

Authors:  Valentina R Minciacchi; Michael R Freeman; Dolores Di Vizio
Journal:  Semin Cell Dev Biol       Date:  2015-02-23       Impact factor: 7.727

6.  Inhibition of oncogenic epidermal growth factor receptor kinase triggers release of exosome-like extracellular vesicles and impacts their phosphoprotein and DNA content.

Authors:  Laura Montermini; Brian Meehan; Delphine Garnier; Wan Jin Lee; Tae Hoon Lee; Abhijit Guha; Khalid Al-Nedawi; Janusz Rak
Journal:  J Biol Chem       Date:  2015-08-13       Impact factor: 5.157

7.  Meeting report: Metastasis Research Society-Chinese Tumor Metastasis Society joint conference on metastasis.

Authors:  Katherine Bankaitis; Lucia Borriello; Thomas Cox; Conor Lynch; Andries Zijlstra; Barbara Fingleton; Miodrag Gužvić; Robin Anderson; Josh Neman
Journal:  Clin Exp Metastasis       Date:  2017-03-04       Impact factor: 5.150

Review 8.  Nucleating actin for invasion.

Authors:  Alexander Nürnberg; Thomas Kitzing; Robert Grosse
Journal:  Nat Rev Cancer       Date:  2011-02-10       Impact factor: 60.716

9.  The distinct traits of extracellular vesicles generated by transformed cells.

Authors:  Marc A Antonyak; Richard A Cerione
Journal:  Small GTPases       Date:  2016-11-16

Review 10.  The role of exosomes in allograft immunity.

Authors:  Sandhya Bansal; Monal Sharma; Ranjithkumar R; T Mohanakumar
Journal:  Cell Immunol       Date:  2018-06-07       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.